especially warfarin, have become standard treatment for reducing the incidence of strokes and systemic emboli in patients with nonvalvular atrial fibrillation (NVAF). The randomized controlled ...

The following is a summary of “Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: ...

For this understudied population, the findings may offer some reassurance as apixaban is already the most prescribed OAC in the general population of the U.S. and in people with H ...

The results showed that patients taking diltiazem had a 20% higher risk of being hospitalized or dying due to serious ...

They also base their decisions to stop anticoagulants on past experiences with people who took the anticoagulant warfarin, Mitchell said. Up until 2012, warfarin was the only option to treat Afib.

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and its incidence increases with age. Current data suggest that anticoagulation with warfarin or dabigatran is far superior to ...

In this randomized controlled trial, abelacimab led to significantly lower rates of major or clinically relevant nonmajor ...

Discover how botanical and nutrient therapies provided adjunctive support for a 76-year-old patient with treatment-resistant ...

In this randomized controlled trial, among patients with atrial fibrillation requiring anticoagulation therapy, asundexian ...

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...